Can Pfizer Bank on New Immunotherapy Bavencio for Growth? – Zacks.com
|
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Zacks.com As demand for immuno-oncology drugs and their combinations rises, Pfizer, Inc.'s (PFE – Free Report) newly approved immunotherapy, Bavencio, is being considered a significant top-line driver for this New York-based pharma giant. Pfizer's shares are up … |
